Sarepta Therapeutics (SRPT) Net Margin (2010 - 2026)

Sarepta Therapeutics' Net Margin history runs 15 years deep, the most recent figure standing at 45.29% for Q1 2026.

• On a quarterly basis, Net Margin rose 38093.0% year-over-year to 45.29% in Q1 2026; TTM through Mar 2026 was 2.98%, a 1829.0% increase from a year earlier, with the FY2025 full-year figure at 38.27%, down 5064.0% from the prior year.
• Net Margin grew to 45.29% in Q1 2026 per SRPT's latest filing, from 63.87% in the prior quarter.
• Across five years, Net Margin topped out at 45.29% in Q1 2026 and bottomed at 335.64% in Q1 2025.
• The 5-year median for Net Margin is 9.16% (2023), against an average of 47.39%.
• Across the five-year window, Net Margin slumped 34448 bps in 2025 and surged 38093 bps in 2026, its largest moves.
• Year by year, Net Margin stood at 38.02% in 2022, then sank by 89 bps to 4.22% in 2023, then surged by 472 bps to 24.12% in 2024, then plunged by 365 bps to 63.87% in 2025, then jumped by 171 bps to 45.29% in 2026.
• Per Business Quant, the three latest SRPT Net Margin figures stand at 45.29% (Q1 2026), 63.87% (Q4 2025), and 45.06% (Q3 2025).